Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
Prostate Cancer & Prostatic Diseases, 05/31/2012
Clinical Article
Egerdie RB et al. – In men with prostate cancer receiving androgen deprivation therapy, significantly higher bone mineral density response rates were observed with denosumab vs placebo. Patients with lower baseline T–scores benefited the most from denosumab treatment.



